For the Inventor, By the Inventor

Enter inventor name

Paolo Pevarello

USPTO Granted Patents = 48 (Patent Applications = 9)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 16)

Average Co-Inventor Count = 5.3

ph-index = 17

Forward Citations = 806(Granted Patents)

Location History:

Madrid, ES (2008 - 2011)
Bresso, IT (2013 - 2023)
Pavia, IT (1993 - 2024)

Company Filing History:

Nerviano Medical Sciences S.r.l.

Pharmacia & Upjohn S.p.a.

Farmitalia Carlo Erba S.r.l.

Pharmacia Italia S.p.a.

Newron Pharmaceuticals S.p.a.

7. 3 out of 5,444

University of Texas System

Golgi Neurosciences S.r.l.

9. 1 out of 523

Pharmacia & Upjohn Company

Centro Nacional De Investigaciones Oncologicas (cnio)

11. 1 out of 23

Pfizer Italia S.r.l.

Pharmacia & Tubjohn Spa

Breye Therapeutics Aps

14. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

Loading Chart...

Loading Chart...

48 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12258337 - Bicyclic CX3CR1 receptor agonists (2025-03-25),

2. 11958839 - Bicyclic CX3CR1 receptor agonists (2024-04-16),

3. 11623919 - Heterocyclic P2X7 antagonists (2023-04-11),

4. 11597702 - Substituted pyrazoles FFA4/GPR120 receptor agonists (2023-03-07),

5. 11155538 - Bicyclic CX3CR1 receptor agonists (2021-10-26),

6. 10669267 - Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists (2020-06-02),

7. 10280176 - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors (2019-05-07),

8. 10167281 - Substituted thiazole or oxazole P2X7 receptor antagonists (2019-01-01),

9. 9718812 - Substituted thiazole or oxazole P2X7 receptor antagonists (2017-08-01),

10. 9637497 - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors (2017-05-02),

11. 9464090 - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors (2016-10-11),

12. 9447029 - Fluorinated arylalkylaminocarboxamide derivatives (2016-09-20),

13. 9012487 - Bicyclo-pyrazoles active as kinase inhibitors (2015-04-21),

14. 8981089 - Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors (2015-03-17),

15. 8785448 - Substituted pyrrolo-pyrazole derivatives as kinase inhibitors (2014-07-22),

Title: The Innovative Mind of Paolo Pevarello

Introduction: Paolo Pevarello, a talented inventor hailing from Pavia, Italy, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Paolo Pevarello holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: With a career spanning over two decades, Paolo Pevarello has worked with leading research institutions and tech companies, consistently pushing the boundaries of what is possible in the world of inventions. His passion for creating solutions to complex problems has led to the development of cutting-edge technologies that have the potential to revolutionize various industries.

Collaborations: Paolo Pevarello has collaborated with top universities and multinational corporations, fostering a culture of innovation and knowledge-sharing. His ability to work effectively in multidisciplinary teams has resulted in the successful implementation of numerous projects that have garnered international recognition.

Conclusion: In conclusion, Paolo Pevarello stands as a visionary inventor whose relentless pursuit of innovation has left an indelible mark on the world of technology. His passion for creating transformative solutions continues to inspire future generations of inventors and innovators.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…